Alnylam Pharmaceuticals, Inc.
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE

Abstract:

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., Alzheimer's disease, atherosclerosis, or inflammation of the choroid plexus (ChP).